BioVie Targets Parkinson’s, Long COVID & Liver Disease With Anti-Inflammatory Therapy

For biotech investors and healthcare innovators, this New to The Street interview features Cuong Do, CEO of BioVie, discussing the company’s fully enrolled Parkinson’s disease trial evaluating its drug candidate designed to reduce neuroinflammation and insulin resistance rather than simply increasing dopamine, with potential to improve both motor and non-motor symptoms and possibly modify disease progression, and with top-line data expected soon.

BioVie is also advancing a long COVID study at leading medical centers including Mount Sinai, Mayo Clinic, Yale, UCSF, and Stanford to address fatigue, brain fog, and cognition issues linked to inflammation, while preparing financing to launch a Phase 3 trial for ascites, a severe end-stage liver disease with high mortality, positioning 2026 as a catalyst-driven year across multiple indications.
#BioVie
#NewToTheStreet
#ParkinsonsDisease
#LongCovid
#Biotech
#ClinicalTrials
#Neuroinflammation
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#LiverDisease
#Ascites
#BiotechStocks
#InvestorInsights